AlphaMark Advisors LLC purchased a new position in shares of HealthEquity, Inc. (NASDAQ:HQY – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,592 shares of the company’s stock, valued at approximately $375,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in HealthEquity by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 8,619,499 shares of the company’s stock worth $571,473,000 after acquiring an additional 104,084 shares in the last quarter. Clearbridge Investments LLC increased its holdings in HealthEquity by 6.9% in the fourth quarter. Clearbridge Investments LLC now owns 2,357,572 shares of the company’s stock valued at $156,307,000 after buying an additional 152,897 shares during the last quarter. Mackenzie Financial Corp raised its stake in HealthEquity by 58.2% during the fourth quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company’s stock valued at $119,831,000 after buying an additional 664,979 shares in the last quarter. Franklin Resources Inc. lifted its holdings in HealthEquity by 7.0% during the 4th quarter. Franklin Resources Inc. now owns 1,480,655 shares of the company’s stock worth $98,167,000 after buying an additional 96,583 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of HealthEquity by 8.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,409,740 shares of the company’s stock worth $93,466,000 after acquiring an additional 108,108 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.
HealthEquity Stock Performance
Shares of HealthEquity stock traded up $0.42 on Monday, hitting $86.62. The stock had a trading volume of 658,987 shares, compared to its average volume of 608,539. The stock has a market cap of $7.54 billion, a price-to-earnings ratio of 94.15, a price-to-earnings-growth ratio of 1.45 and a beta of 0.55. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.44. HealthEquity, Inc. has a twelve month low of $61.32 and a twelve month high of $88.26. The business’s 50 day moving average is $81.14 and its two-hundred day moving average is $78.32.
Insider Transactions at HealthEquity
In related news, CEO Jon Kessler sold 32,326 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $82.83, for a total value of $2,677,562.58. Following the sale, the chief executive officer now directly owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other HealthEquity news, CEO Jon Kessler sold 32,326 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $82.83, for a total transaction of $2,677,562.58. Following the sale, the chief executive officer now owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Vice Chairman Stephen Neeleman sold 2,080 shares of the stock in a transaction on Friday, June 7th. The shares were sold at an average price of $85.01, for a total value of $176,820.80. Following the completion of the transaction, the insider now owns 90,515 shares of the company’s stock, valued at $7,694,680.15. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,806 shares of company stock valued at $2,888,383. Company insiders own 2.20% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Barrington Research raised their target price on shares of HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. KeyCorp raised their price target on HealthEquity from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. Raymond James upped their price objective on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Robert W. Baird boosted their price target on shares of HealthEquity from $98.00 to $104.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 4th. Finally, Bank of America raised their price objective on shares of HealthEquity from $97.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.67.
Check Out Our Latest Report on HQY
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
- Five stocks we like better than HealthEquity
- Stock Analyst Ratings and Canadian Analyst Ratings
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Insider Buying Explained: What Investors Need to Know
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What Investors Need to Know to Beat the Market
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.